Alofisel
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
DRUG OVERVIEW
Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection. The therapy is being developed in Crohn’s disease for the treatment of complex perianal fistulas which show an inadequate response to at least one conventional or biologic therapy, including antibiotics, immunosuppressants, or anti-tumor necrosis factor (TNF) agents.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Alofisel : Crohn’s disease
LIST OF FIGURES
13 Figure 11: Datamonitor Healthcare’s drug assessment summary of Cimzia in Crohn’s disease
15 Figure 40: Top treatment challenges in Crohn’s disease
18 Figure 41: Summary of future usage of biosimilar infliximab at one year and three years post-launch
LIST OF TABLES
5 Table 1: Alofisel drug profile
7 Table 2: Alofisel Phase III data in Crohn’s disease
10 Table 3: Alofisel Phase III trial in Crohn’s disease
12 Table 4: Alofisel Phase I/II data in Crohn’s disease
19 Table 5: Alofisel sales for Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016–25
Upadacitinib 
Sign up to the